Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 189

Sort by

Sort Order Select

Journal Articles

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Hind Al Azzawi, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 1379.

https://doi.org/10.1182/blood-2019-131348

Published: 2019

Journal Articles

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, MD PhD, Seung Tae Lee, MD PhD, Rong Chen, PhD, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD, William Plunkett, PhD

Blood (2019) 134 (Supplement_1): 1761.

https://doi.org/10.1182/blood-2019-128956

Published: 2019

Journal Articles

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Wittawat Chantkran, MD MSc, Daniella Zheleva, PhD, Sheelagh Frame, PhD, Ya-Ching Hsieh, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 3938.

https://doi.org/10.1182/blood-2019-124072

Published: 2019

Journal Articles

Control of HIV-1 Infection By Ferroportin Q248H Mutation

Namita Kumari, PhD, Seyed Mehdi Nouraie, PhD MD, Hatajai Lassiter, MS, BS, Asrar Ahmad, PhD, Kathryn Anastos, Jason Lazar, Seble Kassaye, Bradley Aouizerat, Audrey French, Stephen Gange, Adaora Adimora, Neale Weitzmann, Margaret Fischl, Mirjam-Colette Kempf, Sergei Nekhai, PhD

Blood (2019) 134 (Supplement_1): 953.

https://doi.org/10.1182/blood-2019-128685

Published: 2019

Journal Articles

Role of AML1-ETO Related Fusion Circular RNA in the Growth of Leukemia Cells

Ying Wang, MD, Yingxi Xu, PhD, Qian Liu, Haiyan Xing, MS, Zheng Tian, BS, Kejing Tang, BS, Qing Rao, MS, Min Wang, MD, Jianxiang Wang, MD

Blood (2018) 132 (Supplement 1): 5130.

https://doi.org/10.1182/blood-2018-99-112728

Published: 2018

Journal Articles

A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups

Blood (2018) 132 (Supplement 1): 5284.

https://doi.org/10.1182/blood-2018-99-118062

Published: 2018

Journal Articles

Restriction of HIV-1 Infection in Sickle Cell Disease and Trait

Namita Kumari, PhD, Miguel de Mulder, PhD, Javed Khan, PhD, Asrar Ahmad, PhD, Songping Wang, Hatajai Lassiter, Nathan Smith, Nowah Kokou Apeadoufia Afangbedji, Andrey Ivanov, PhD, Mitsu Shah, Sharmin Diaz, Sohail Rana, MD, Douglas Nixon, PhD, Sergei Nekhai, PhD

Blood (2018) 132 (Supplement 1): 2337.

https://doi.org/10.1182/blood-2018-99-117029

Published: 2018

Journal Articles

Targeting Distinct Promoter- and Enhancer-Driven Dependencies in Multiple Myeloma

Chandraditya Chakraborty, PhD, Mehmet Kemal Samur, PhD, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 3156.

https://doi.org/10.1182/blood-2018-99-112583

Published: 2018

Journal Articles

Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2

Meidan Ying, Xuejing Shao, Hui Jing, Yujia Liu, Xiaotian Qi, Ji Cao, Yingqian Chen, Senfeng Xiang, Hua Song, Ronggui Hu, Guoqing Wei, Bo Yang, Qiaojun He

Blood (2018) 131 (24): 2698–2711.

https://doi.org/10.1182/blood-2017-10-813139

Published: 2018

Includes: Supplemental data

Journal Articles

Restriction of HIV-1 Infection in Sickle Cell Disease Trait

Namita Kumari, PhD, Javed Khan, Tatiana Ammosova, PhD, Asrar Ahmad, Sharmin Diaz, NP, Sohail Rana, MD, Sergei Nekhai, PhD

Blood (2017) 130 (Supplement 1): 940.

https://doi.org/10.1182/blood.V130.Suppl_1.940.940

Published: 2017

Journal Articles

Identifying High-Risk Phenotypes Using Three-Way Feature Interactions in Multiple Myeloma: An Analysis of Publically Available Mmrf Commpass Study

Caleb K Stein, MS, Yan Asmann, PhD, P. Leif Bergsagel, MD

Blood (2017) 130 (Supplement 1): 3034.

https://doi.org/10.1182/blood.V130.Suppl_1.3034.3034

Published: 2017

Journal Articles

CT7001, a Novel Orally Bio-Available CDK7 Inhibitor, Is Highly Active in in-Vitro and in-Vivo Models of AML

Kristopher Clark, PhD, Edward Ainscow, PhD, Adam Peall, Stuart Thomson, PhD, Andrew Leishman, PhD, Sullivan Elaine, PhD, Simak Ali, PhD, Raoul Coombes, MD, Anthony Barrett, PhD, Ash Kumar Bahl, PhD

Blood (2017) 130 (Supplement 1): 2645.

https://doi.org/10.1182/blood.V130.Suppl_1.2645.2645

Published: 2017

Journal Articles

Beyond JAK-STAT: Contribution of Abi-1, STAT3, and NF-κB Signaling to Pathogenesis of Myeloproliferative Neoplasms

Anna Dorota Chorzalska, PhD, John Morgan, PhD, Diana Olguta Treaba, MD, Adam J Olszewski, MD, Kara Lombardo, Roberta Zini, BSc, PhD, Annalisa Pacilli, PhD, Alexander Tepper, John L. Reagan, MD, Leszek Kotula, MD, Peter J. Quesenberry, MD, Philip Gruppuso, MD, Rossella Manfredini, BSc, PhD, Alessandro M. Vannucchi, Patrycja Dubielecka, PhD

Blood (2017) 130 (Supplement 1): 4210.

https://doi.org/10.1182/blood.V130.Suppl_1.4210.4210

Published: 2017

Journal Articles

Hemin and Iron Modulated Intrinsic Cellular Factors Regulate HIV-1 Replication in Sickle Cell Disease

Namita Kumari, PhD, Miguel de Mulder, Nowah Kokou Apeadoufia Afangbedji, Songping Wang, Sharmin Diaz, NP, Douglas Nixon, Sergei Nekhai, PhD

Blood (2017) 130 (Supplement 1): 3492.

https://doi.org/10.1182/blood.V130.Suppl_1.3492.3492

Published: 2017

Journal Articles

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Rita Assi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan Kadia, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Nitin Jain, MD, Naval Daver, MD, Taisuke Uehara, Takashi Owa, PhD, Gautam Borthakur, MD

Blood (2017) 130 (Supplement 1): 1380.

https://doi.org/10.1182/blood.V130.Suppl_1.1380.1380

Published: 2017

Journal Articles

SF3B1 Interactions with Chromatin Are Dynamic and Regulated in a Cell Cycle-Dependent Manner

Tushar Murthy, MS, Theresa Bluemn, Manoj M. Pillai, MD, Alex C Minella, MD

Blood (2016) 128 (22): 1480.

https://doi.org/10.1182/blood.V128.22.1480.1480

Published: 2016

Journal Articles

Cdkn3 Knockout Mice Develop Hematopoietic Malignancies

Zejin Sun, MD PhD, Donna Cerabona, Ying He, Grzegorz Nalepa, MD PhD

Blood (2016) 128 (22): 1537.

https://doi.org/10.1182/blood.V128.22.1537.1537

Published: 2016

Journal Articles

Retinoic Acid Receptor Alpha Expression Drives Cell-Cycle Progression and Is Associated with Increased Sensitivity to Retinoids in Peripheral T-Cell Lymphoma

Rebecca L Boddicker, PhD, Xueju Wang, Surendra Dasari, PhD, Grzegorz S. Nowakowski, MD, Konstantinos N Lazaridis, Eric D Wieben, Marshall E. Kadin, MD, Andrew L Feldman, MD

Blood (2016) 128 (22): 1749.

https://doi.org/10.1182/blood.V128.22.1749.1749

Published: 2016

Journal Articles

Limb-Bud and Heart (LBH), Target of Mir-191, Is a Novel Positive Regulator of Erythroid Differentiation

Wentian Wang, Yang Yang, Yongjuan Duan, Huijuan Zhao, Xiao Hu, PhD

Blood (2016) 128 (22): 1199.

https://doi.org/10.1182/blood.V128.22.1199.1199

Published: 2016

Journal Articles

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Takayuki Tabayashi, MD PhD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Anan-Nemoto, MDPhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 3256.

https://doi.org/10.1182/blood.V128.22.3256.3256

Published: 2016

NARROW

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Control of HIV-1 Infection By Ferroportin Q248H Mutation

Role of AML1-ETO Related Fusion Circular RNA in the Growth of Leukemia Cells

A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups

Restriction of HIV-1 Infection in Sickle Cell Disease and Trait

Targeting Distinct Promoter- and Enhancer-Driven Dependencies in Multiple Myeloma

Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2

Restriction of HIV-1 Infection in Sickle Cell Disease Trait

Identifying High-Risk Phenotypes Using Three-Way Feature Interactions in Multiple Myeloma: An Analysis of Publically Available Mmrf Commpass Study

CT7001, a Novel Orally Bio-Available CDK7 Inhibitor, Is Highly Active in in-Vitro and in-Vivo Models of AML

Beyond JAK-STAT: Contribution of Abi-1, STAT3, and NF-κB Signaling to Pathogenesis of Myeloproliferative Neoplasms

Hemin and Iron Modulated Intrinsic Cellular Factors Regulate HIV-1 Replication in Sickle Cell Disease

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

SF3B1 Interactions with Chromatin Are Dynamic and Regulated in a Cell Cycle-Dependent Manner

Cdkn3 Knockout Mice Develop Hematopoietic Malignancies

Retinoic Acid Receptor Alpha Expression Drives Cell-Cycle Progression and Is Associated with Increased Sensitivity to Retinoids in Peripheral T-Cell Lymphoma

Limb-Bud and Heart (LBH), Target of Mir-191, Is a Novel Positive Regulator of Erythroid Differentiation

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only